Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Enterprise Value: 2009-2025

Historic Enterprise Value for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $5.6 billion.

  • Cytokinetics' Enterprise Value rose 7.95% to $5.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 billion, marking a year-over-year decrease of 5.75%. This contributed to the annual value of $4.5 billion for FY2024, which is 40.89% down from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Enterprise Value is $5.6 billion, which was up 81.81% from $3.1 billion recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Enterprise Value registered a high of $7.6 billion during Q4 2023, and its lowest value of $1.1 billion during Q2 2021.
  • Over the past 3 years, Cytokinetics' median Enterprise Value value was $4.5 billion (recorded in 2024), while the average stood at $4.4 billion.
  • As far as peak fluctuations go, Cytokinetics' Enterprise Value soared by 232.93% in 2021, and later crashed by 42.13% in 2025.
  • Quarterly analysis of 5 years shows Cytokinetics' Enterprise Value stood at $3.4 billion in 2021, then climbed by 5.97% to $3.6 billion in 2022, then surged by 113.17% to $7.6 billion in 2023, then slumped by 40.89% to $4.5 billion in 2024, then increased by 7.95% to $5.6 billion in 2025.
  • Its Enterprise Value was $5.6 billion in Q3 2025, compared to $3.1 billion in Q2 2025 and $3.8 billion in Q1 2025.